APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moder...

por Viscusi, Eugene R, Skobieranda, Franck, Soergel, David G, Cook, Emily, Burt, David A, Singla, Neil
Publicado 2019

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

por Nafziger, Anne N., Arscott, Kelly A., Cochrane, Kristina, Skobieranda, Franck, Burt, David A., Fossler, Michael J.
Publicado 2019

Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing In...

por Ayad, Sabry, Demitrack, Mark A., Burt, David A., Michalsky, Cathy, Wase, Linda, Fossler, Michael J., Khanna, Ashish K.
Publicado 2020

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Mode...

por Singla, Neil K., Skobieranda, Franck, Soergel, David G., Salamea, Monica, Burt, David A., Demitrack, Mark A., Viscusi, Eugene R.
Publicado 2019

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute p...

por Singla, Neil, Minkowitz, Harold S, Soergel, David G, Burt, David A, Subach, Ruth Ann, Salamea, Monica Y, Fossler, Michael J, Skobieranda, Franck
Publicado 2017